Background The quadrivalent human papillomavirus vaccine (qHPV) is FDA-approved for
use in males 9 to 26 years old to prevent anogenital condyloma. The objective of this study …

Human papillomavirus (HPV)-related diseases are highly prevalent in men worldwide,
comprising external anogenital condyloma, anal intraepithelial neoplasia (AIN), penile …

BACKGROUND: Men who have sex with men have increased prevalence of both human
papillomavirus and anogenital condyloma. OBJECTIVE: Risk factors for multiple treatment …

Background. Most squamous cell anal cancers and precancerous lesions are attributed to
human papillomavirus (HPV) infection. By preventing HPV infection, quadrivalent HPV …

Importance Determining vaccine dose-level protection is essential to minimize program
costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination …

Background The rate of anal cancer is increasing among both women and men, particularly
men who have sex with men. Caused by infection with human papillomavirus (HPV) …

Background & Aims: The incidence of anal cancer is higher in patients with anal canal
condyloma, a sexually transmitted disease, than in the general population. We determined …

Abstract On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP)
recommended routine use of quadrivalent human papillomavirus (HPV) vaccine (HPV4; …

Objective HPV causes~ 90% of anal cancer and HPV16 is the type most commonly
associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We …

Objectives The incidence of human papillomavirus (HPV)‐associated anal cancer is
increasing. Men who have sex with men (MSM), particularly those coinfected with HIV, are …